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A multicentre validation of Metasin: a molecular assay for the intraoperative assessment of
sentinel lymph nodes from breast cancer patients
Aims: Treatment strategies for breast cancer continue
to evolve. No uniformity exists in the UK for the man-
agement of node-positive breast cancer patients. Most
centres continue to use conventional histopathology of
sampled sentinel lymph nodes (SLNs), which requires
delayed axillary clearance in up to 25% of patients.
Some use touch imprint cytology or frozen section for
intraoperative testing, although both have inherent
sensitivity issues. An intraoperative molecular diag-
nostic approach helps to overcome some of these limi-
tations. The aim of this study was to assess the clinical
effectiveness of Metasin, a molecular method for the
intraoperative evaluation of SLNs.
Methods and results: RNA from 3296 lymph nodes
from 1836 patients undergoing SLN assessment was
analysed with Metasin. Alternate slices of tissue
were examined in parallel by histology. Cases
deemed to be discordant were analysed by protein
gel electrophoresis. There was concordance between
Metasin and histology in 94.1% of cases, with a
sensitivity of 92% [95% confidence interval (CI)
88–94%] and a specificity of 97% (95% CI
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95–97%). Positive and negative predictive values
were 88% and 98%, respectively. Over half of the
discordant cases (4.4%) were ascribed to tissue allo-
cation bias (TAB).
Conclusions: Clinical validation of the Metasin assay
suggests that it is sufficiently sensitive and specific
to make it fit for purpose in the intraoperative
setting.
Keywords: axillary clearance, breast cancer, CK19, intraoperative, mammaglobin, Metasin, molecular, PCR,
sensitivity, sentinel lymph node, specificity
Introduction
Axillary nodal status remains an important prognos-
tic indicator in breast cancer patients.1,2 The sam-
pling and assessment of sentinel lymph nodes (SLNs)
is the accepted standard for nodal staging in breast
cancer in the UK, although there is marked diver-
gence in local practice, with most centres (85.6%)
carrying out conventional histopathology with a two-
stage axillary clearance.3–5 A minority of centres
carry out intraoperative frozen section (FS) (3.8%),
touch imprint cytology [DAB cytology (DABc)]
(3.1%), or intraoperative molecular testing of SLNs
(7.5%).5 These methodologies have limitations in the
context of one-step axillary clearance. Conventional
histopathology has the disadvantage of a delayed
time course of 2–3 days, and FS and DABc, although
highly specific, have inherent sensitivity issues.6–9
The molecular approach has the disadvantages of
cost and disruption resulting from the implementa-
tion of a new technology, but it offers the advantages
of enhanced sensitivity and specificity.
Detailed histopathological studies of SLNs and axil-
lary lymph nodes resected in unselected patient
groups have identified nodal involvement in 25–35%
of patients,10–13 indicating that selective identification
of these patients could avoid the consequences of axil-
lary clearance and its complications in the remaining
non-involved group. Conventional histological
haematoxylin and eosin staining and assessment of
SLNs precludes surgical treatment in a one-step pro-
cess. Preoperative ultrasound-based staging of the
axilla with fine needle aspiration cytology (FNAC) or
needle biopsy can effectively provide a one-step opera-
tive procedure for both breast surgery and axillary
clearance, but the radiological axillary staging proce-
dure is inaccurate and prone to overlooking node-
positive cases, as it can miss both macrometastases
and micrometastases.12–16
Examination of DABc preparations and FS diagno-
sis of SLNs are currently used in clinical practice as a
means for rapid assessment of the SLN, facilitating
axillary clearance in a one-step process, particularly
in the USA.7 However, these methods have varying
degrees of uncertainty in diagnosing nodal involve-
ment.6,8,9 In the absence of a definitive cost-effective
assay, many laboratories in the UK still carry out
SLN sampling assessment and subsequent axillary
clearance as a two-stage procedure.5,17 The disadvan-
tages of this approach are considerable: for the
patient, not knowing whether there is a need for a
second procedure; for the National Health Service
(NHS), the cost of the second procedure (£5500 per
patient in the UK)18,19 and the morbidity associated
with this process; and for the surgeon, the inherent
disadvantages of re-entering a healing surgical
wound site, weeks later. In contrast, a single opera-
tive procedure is attractive in terms of patient choice,
cost, and the avoidance of a second procedure in the
10–20% of node-positive patients (post-axillary
sonography).14–16
Advances associated with molecular diagnosis have
provided tools for the rapid and accurate intraopera-
tive testing of SLNs.20–24 Although such tools require
the implementation of new technologies, they promise
the combined benefits of enhanced speed, simplicity,
sensitivity, and specificity, thus facilitating intraopera-
tive axillary clearance of lymph nodes as a one-step
process in breast cancer patients.20–24 We have previ-
ously described the Metasin assay,24 which uses a
similar methodology to Genesearch (Veridex LLC, NJ,
USA), now withdrawn from sale because of the lack
of uptake in the USA and commercialization of this
product worldwide.25 Like Genesearch,20–22 Metasin
utilizes real-time quantitative reverse transcription
polymerase chain reaction (RT-qPCR) to probe for the
presence of two predictive markers for the detection
of epithelial cells, i.e. cytokeratin 19 (CK19) and
mammaglobin (MGB); a third marker, porphobilino-
gen deaminase (PBGD), provides an internal positive
amplification control to confirm the presence of
amplifiable RNA. A positive result for either or both
of the epithelial cell-specific markers and the positive
control suggests the presence of metastatic disease
within the tested lymph node. Our previous report24
described the rationale for the use of these biomarkers
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on a cohort of 154 cases, and validated its use on a
further 193 samples. We now extend this small study
with a larger cohort of breast cancer patients, and
describe the clinical validation of Metasin in 1836
cases and report an overall discordance rate of 4.4%.
Materials and methods
C O N S E N T A N D E T H I C A L A P P R O V A L
The study was ethically approved by the Essex 2
Research Ethics Committee (07/H0302/129 & REC
10/H301/24). All patients were recruited after the
implementation of the ‘New Start’ programme.26,27
P A T I E N T S E L E C T I O N
Participants were recruited from five centres, with a
recruitment target in excess of 1200 cases to ensure
determination of statistical significance based on
power analysis. Patients subjected to SLN sampling
were included in the study if they had biopsy-proven
breast cancer and had been previously radiologically
staged as negative for axillary disease by a combina-
tion of ultrasound and FNAC. Cases that were radio-
logically deemed to be positive and underwent FNAC
were excluded if these were positive, as these patients
would undergo axillary node clearance routinely in a
one-step procedure. Informed consent was obtained
for the intraoperative Genesearch assay analysis and
for the prospective intraoperative analysis with Meta-
sin. There were no other exclusion criteria. Standards
for Reporting of Diagnostic Accuracy (STARD)-based
tabulated detail is provided in Data S1.
There were two groups: an analytical validation
group, and a prospective validation group. The recruit-
ment period for the analytical validation group was
from March 2008 to August 2010. Homogenates,
and/or RNA, were obtained from 448 cases examined
with Genesearch. From August 2010 to August 2013,
1388 cases were examined with Metasin for the
prospective validation group. Investigators at Princess
Alexandra Hospital (PAH), Harlow were blinded to the
results of the outcome of Genesearch and histology,
and axillary clearance data. The case-based results of
the patient demographics, outcomes of Genesearch,
histological outcomes of the SLNs and axillary clear-
ances (Table S1) were obtained and collated at PAH.
Analytical validation (Table S1)
Lymph node homogenates and RNA samples
(n = 448) previously analysed with Genesearch were
obtained from four centres that had been using Gene-
search: Queen Alexandra Hospital, Portsmouth
(n = 190); Royal Free Hospital, London (n = 45);
University Hospital of Wales, Cardiff (n = 70);28 and
Prince Philip Hospital, Llanelli, Wales (n = 143).
Cases from PAH (n = 154) were excluded, as these
had been previously published in the validation
paper.24 Three centres provided frozen lymph node
homogenates of volumes ranging from 1 ml to 5 ml,
which were stored at 80°C; the Royal Free Hospital
provided RNA, which had also been stored at 80°C.
Homogenates and RNA were transported on dry ice
to PAH.
Prospective validation (three centres)
Standardization of the assay across the three centres
was achieved by using a single source and batch of
RT-qPCR primers and probes (TIB Molbiol, Berlin,
Germany), ensuring PCR cycling parameters and
appropriate machine settings.24 The outcome of the
assay was compared with histology, the gold stan-
dard.
Once Metasin had been validated for local use,24 a
further 1388 cases were recruited into the study from
three centres (PAH NHS Trust, Harlow, Queen
Alexandra Hospital NHS Trust, Portsmouth, and
Prince Philip Hospital, Llanelli, Wales). These patients
consented to undergo Metasin assay after an in-house
validation of the assay in each of the three centres.
The outcomes of the results of these ‘live’ cases were
reported to the surgeons intraoperatively.24 SLNs
from each patient were prepared for intraoperative
analysis (see below), and the results were reported for
surgeons to carry out axillary clearance in positive
cases. If positivity for metastatic disease was found,
axillary clearance was carried out in a one-step pro-
cedure. Metasin assay was repeated at PAH for a rep-
resentative number of cases (358), to confirm the
validity of locally reported results.
A S S E S S M E N T O F S L N S : L O C A L I Z A T I O N O F L Y M P H
N O D E S A N D P R E P A R A T I O N F O R I N T R A O P E R A T I V E
A N A L Y S I S
The SLNs were identified by use of a combined tech-
nique employing radioactively (TcM99m) labelled
nanocolloid and 2 ml of diluted Patent V blue dye.27
Excess extracapsular fat was removed from the lymph
nodes, which were weighed and sliced into 2-mm sec-
tions, with alternate slices being allocated for homog-
enization for molecular assessment (Genesearch and/
or Metasin) and histopathological assessment. SLNs
were serially sliced at standardized 2-mm intervals by
consultant pathologists and trained biomedical
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scientists (BMSs). No cases were excluded on the basis
of size or weight. The numbers of SLNs submitted
varied from one to up to six initially, but averaged
two to three once the procedure was well established.
H I S T O P A T H O L O G I C A L P R O C E S S I N G
Slices for histology were processed individually
according to local histopathology protocols. All tissue
submitted for histopathology was analysed with con-
ventional methods employing formalin fixation and
paraffin embedding. SLNs were analysed at at least
three levels in all of the centres. The Royal Free
Hospital step-sectioned at 100 lm through the entire
tissue block for discordant cases. In discordant cases,
slides were examined by two experienced consultant
histopathologists during this validation period (the
local reporting pathologist and the lead breast pathol-
ogist). Discordant node analysis included examination
of a further three to five levels with immunostaining
for cytokeratins (MNF116). Cases that continued to
be discordant despite examination of deeper levels on
the SLN were examined with a view to determining
the cause of the discordance. These ‘discordant’ cases
were further examined by examination of deeper
levels on axillary clearances (selectively) and, where
protein lysates were available, by protein gel analysis
of homogenates to determine the presence of cytoker-
atin protein.
H I S T O L O G Y O F A X I L L A R Y L Y M P H N O D E
C L E A R A N C E
All centres carried out single-level histological analy-
sis of all dissected lymph nodes. In selected cases dur-
ing discordant analysis, nodes from the axillary
clearance specimens were examined at deeper levels
(up to five levels) by cutting step sections at 100 lm
through the paraffin wax block to identify the pres-
ence of metastatic disease.
R N A P R E P A R A T I O N A N D R T - Q P C R A S S A Y
RNA extraction of the SLN slices and the RT-qPCR
assay were carried out as described previously.24
N O D A L D I S E A S E A N D P A T I E N T M A N A G E M E N T
Macrometastases/micrometastases/isolated tumour cells
(ITCs)—histological criteria
Macrometastases were defined histologically as
>2 mm, and micrometastases as ≤2 mm and
>0.2 mm.29–31 ITCs were defined histologically as
tumour size ≤0.2 mm or a cluster of 200 tumour
cells in a single histological section.29–31
Macrometastases/micrometastases/ITCs—Metasin criteria
Cases were reported as positive if the RT-qPCR quan-
tification cycle (Cq) values for the molecular analysis
were within predetermined ‘cut-offs’ validated previ-
ously.24,32 Cq values for macrometastases were ≤25
for CK19 and ≤26 for MGB. Cq values for
micrometastases were >25 and <32 for CK19, and
>26 and <32.3 for MGB. ITCs deemed to be negative
were defined by molecular means as >32 for CK19
and >32.3 for MGB. Cq values above these levels
were reported as negative.
Axillary lymph node clearances were carried out
on all macrometastasis and micrometastasis cases.
Local practice changed with time to a more
conservative approach for micrometastasis cases,
with axillary clearances only for macrometastasis
cases in some centres. The different contributing
centres followed their local guidelines for axillary
clearance based on multidisciplinary team discus-
sions dependent on clinical parameters of stage of
disease, size of tumour, histology, and hormone
receptor status.
Discordant cases: defined by case-based discordant
analysis
Cases were deemed to be discordant when the histol-
ogy results (positive or negative) did not correlate
with the intraoperative molecular analysis results
(positive for macrometastasis or micrometastasis; or
negative).
D I S C O R D A N T C A S E A N A L Y S I S B Y P R O T E I N G E L
E L E C T R O P H O R E S I S O F H O M O G E N A T E S F O R C K 1 9
Protein concentrations of homogenates were assessed
with a NanoDrop (Thermo Scientific, DE, USA). Pro-
tein levels were adjusted to a final concentration of
2 lg/ll in loading buffer (1 9 Laemmli sample buf-
fer; BioRad, Hemel Hemstead, UK) containing 5%
b-mercaptoethanol (Sigma-Aldrich, Dorset, UK).
Protein samples were boiled for 5 min at 95°C and
cooled on ice, and 25 ll of each sample was loaded
(50 lg of total protein) onto a 12% sodium dodecyl-
sulphate polyacrylamide gel electrophoresis gel.
Following electrophoresis, proteins were electrotrans-
ferred onto poly(vinylidene difluoride) (PVDF) mem-
branes (Roche Diagnostics, Burgess Hill, UK), which
were then blocked [4% w/v Marvel in Tris-buffered
saline containing 1% Tween -20 (TBS-T)] for 1 h at
room temperature. PVDF membranes were incubated
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with the primary antibodies mouse monoclonal anti-
body raised against CK19 (A53-B/A2; 1:1000;
Abcam, Cambridge, UK) and rabbit anti-glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) (1:1000;
Sigma-Aldrich) in blocking solution overnight at
room temperature. On the following day, PVDF mem-
branes were washed, and incubated in secondary per-
oxidase-labelled anti-species IgG (1:5000; Vector
Laboratories, Peterborough, UK) in blocking solution
for 2 h. After washing with TBS-T, the ECL plus west-
ern blotting detection system (GE Healthcare Life
Sciences, Buckinghamshire, UK) was used to visualize
CK19 and GAPDH antibody complexes, with the
Chemidoc-MP imaging system and IMAGE LAB 4.1 soft-
ware (BioRad, Hemel Hemstead, UK). GAPDH was
used as an internal control to confirm equal sample
loading.
S T A T I S T I C A L A N A L Y S I S
The data were separated into analytical validation
(with Genesearch cases) and prospective validation
(without Genesearch cases) case cohorts. The end-
point of the main analysis was the overall agreement
between histology, Metasin, and Genesearch, where
applicable. This endpoint was assessed after, where
possible, the detailed examination of the SLN at dee-
per levels and immunohistochemistry had been per-
formed. Other aspects of statistical analyses were time
for duration of assay (from receipt of node in the lab
to reporting result to surgical team) and sensitivity,
specificity, positive predictive value (PPV) and nega-
tive predictive value (NPV) of Metasin. Receiver oper-
ator curve (ROC) analysis of datasets was used to
confirm Cq values set for macrometastasis and
micrometastasis determination.
McNemar’s test for significance was used to test the
null hypothesis that there is no difference in SLN out-
come (positive, including macrometastasis and
micrometastasis cases; or negative, including ITC
and negative cases) between histology, Metasin, and
Genesearch. Spearman’s correlation test was also
used to assess the degree of correlation between the
three groups.
P A T I E N T M A N A G E M E N T D U R I N G T H E C O U R S E O F
T H E V A L I D A T I O N S T U D Y
All cases with confirmed breast cancer were assessed
with axillary sonography and FNAC. Outcomes were
discussed at multidisciplinary team meetings. Patients
with negative FNAC results were offered a one-step
procedure with axillary clearance, if positive, follow-
ing intraoperative assessment with Metasin. The risk
of intraoperative assay failure was mitigated by
ensuring that alternate slices of the lymph nodes
were retained for conventional histopathological anal-
ysis. If the assay failed in the intraoperative setting,
the assay was repeated. If, however, the assay failed
again, surgeons were asked to await conventional
histopathological assessment.
Results
P A T I E N T D E M O G R A P H I C S
Details of the patient demographics and relevant clini-
cal information were retrospectively collated, and are
presented in Data S1.
R E S U L T S O F T H E C U T - O F F V A L U E S F O R P O S I T I V E
A N D N E G A T I V E N O D E S , M A C R O M E T A S T A S E S , A N D
M I C R O M E T A S T A S E S
Once all concordant positive cases (between Gene-
search and histology) had been identified, the nodes
were grouped separately into macrometastasis or
micrometastasis cases on the basis of the histology
results and Cq data, as described previously.24,32
Details of the Metasin and histology data for the
analytical validation group with the Genesearch
assay and Metasin are provided in Table S1.
S T A T I S T I C A L A N A L Y S I S
Analytical validation cases—correlation of histology,
Metasin, and Genesearch
Within the analytical validation group comparing
histology with Metasin and Genesearch, there were
significant correlations of positive and negative out-
comes between Metasin and Genesearch (P = 0.015),
between histology and Metasin (P < 0.0001), and
between histology and Genesearch (P < 0.0001),
with McNemar’s test. Spearman’s correlation test also
showed statistically significant correlations, with
P-values of <0.0001 for all three groups.
Prospective validation cases—correlation of histology and
Metasin
The same analysis was applied to all cases with his-
tology and Metasin results, including the cases after
Genesearch was withdrawn. There was a significant
correlation between the two methods (Spearman’s
correlation, P < 0.0001). No statistically significant
difference was found between the outcomes of histol-
ogy and Metasin. This indicates that Metasin gives a
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very similar outcome to the existing gold standard of
histological assessment.
ROC curve analysis of Cq values for macrometastasis/
micrometastasis determination
Cq values for the Metasin markers CK19 and MGB
were computed against histology by use of ROC
analysis for a small subset of cases (results not
shown). The sensitivity, specificity and overall accu-
racy with 95% confidence intervals (CIs) were
obtained, and cut-off points were determined by
maximizing the sensitivity and specificity. The cut-off
points in this analysis for Metasin (CK19 and MGB)
for macrometastasis and micrometastasis was 0.4
from the Cq values determined previously. The MGB
macrometastasis cut-off value was 27.9 as compared
with 26. The overall accuracy and 95% CIs for
Metasin (CK19 and MGB) based on ROC curve anal-
yses were as follows. For CK19, the macrometastasis
cut-off was <25.1, with an accuracy of 0.9597
(95% CI 0.943–0.977), and the micrometastasis cut-
off was <31.7, with an accuracy of 0.783 (95% CI
0.722–0.844). For MGB, the macrometastasis cut-off
was <27.9, with an accuracy of 0.8754 (95% CI
0.843–0.908), and the micrometastasis cut-off was
<32.7, with an accuracy of 0.6662 (95% CI 0.58–
0.75).
M E T A S I N P O O L E D P R O S P E C T I V E A N D V A L I D A T I O N
G R O U P O F 1 8 3 6 C A S E S : H I S T O L O G Y V E R S U S
M E T A S I N
Comparison of Metasin with histology
In total, 1836 cases were tested with Metasin in the
combined prospective and analytical validation
groups. The results as compared with histology are
shown in Table 1 and Figure 1. Of these, 356 cases
(19.4%) were both Metasin-positive and histology-
positive, and 1372 cases (74.7%) were negative with
both. Thirty-two cases (1.7%) were discordant, being
histology-positive and Metasin-negative. Conversely,
49 cases (2.7%) were histology-negative but Metasin-
positive. The overall discordance rate was 4.4%
(Table 1; 32 + 49 = 81 of 1836 cases).
Analysis of lymph nodes in axillary clearance specimen
As Metasin is a predictor of axillary node involve-
ment, we examined the nodes removed at axillary
clearance for histological evidence of involvement of
selected false-positive cases (n = 10). Four cases were
shown to have positive histology in the axillary clear-
ance samples (three macrometastasis cases and one
micrometastasis case).
S E N S I T I V I T Y O F T H E M O L E C U L A R A S S A Y
Genesearch as compared with histology
Once discordance analysis of cases had been carried
out, the sensitivity of Genesearch as compared with
histology was 98% (95% CI 92–99%), and the speci-
ficity was 93% (95% CI 89–95%). Genesearch had a
PPV of 77% and an NPV of 99%. The overall accu-
racy was 94%. The discordance rate of Genesearch as
compared with histology was 6% (Table S1).
Metasin as compared with histology (all cases,
n = 1836)
The sensitivity of Metasin as compared with histology
was 92% (95% CI 89–94%), and the specificity was
97% (95% CI 95–97%). Metasin had a PPV of 88%
and an NPV of 98%. The overall accuracy was 96%.
The discordance rate of Metasin as compared with
histology was 4.4%.
M A C R O M E T A S T A S I S / M I C R O M E T A S T A S I S
P R E D I C T I O N O F M E T A S I N A S C O M P A R E D W I T H
H I S T O L O G Y
The results for the cohort of 356 cases are summa-
rized in Table 2. For the dataset of 356 cases that
were histology-positive and Metasin-positive from
both the analytical and prospective validation data-
sets (total, n = 1836), tumour volume data
(macrometastasis/micrometastasis) were available for
Table 1. Discordant results between histology and Metasin after pooling of retrospective and prospective cases (1836 cases
representing 3297 nodes)
Cases
Discordance
True positive,
no. (%)
True negative,
no. (%)
False negative,
no. (%)
False positive,
no. (%)
Fails,
no. (%)
Total, no.
(%)
Total discordant
cases, no. (%)
After deeper levels on
sentinel node
356.0 (19.4) 1372 (74.7) 32 (1.7) 49 (2.7) 27 (1.5) 1836 (100) 81 (4.4)
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356 cases (Table 3). In two of the positive cases,
there was macrometastasis/micrometastasis discor-
dance between two different nodes, and these have
been included because they are overall case-concor-
dant. Concordance of macrometastasis/micrometasta-
sis prediction was seen in 88.8% (277 + 39 = 316).
Prediction of macrometastasis was seen in 277 of
356 cases (77.8%), and prediction of micrometastasis
in 39 of 356 cases (10.9%). There was discordance
between macrometastasis and micrometastasis predic-
tion of 11.2% (28 + 12 = 40).
P R E D I C T I V E M A R K E R S
Table 3 summarizes the case-based data for marker
positivity for all 405 Metasin-positive cases (inclusive
of the 49 Metasin-positive histology-negative discor-
dant cases). Of these, 224 cases (210 macrometasta-
sis + 14 micrometastasis = 224, 55.3%) were positive
for both CK19 and MGB, 151 cases
(102 + 49 = 151, 37%) were positive for CK19, and
30 (11 + 19 = 30, 7.4%) were positive for MGB only.
Of the 30 cases positive for MGB only, 11 were
macrometastasis cases and 19 were micrometastasis
cases.
P R O T E I N G E L A N A L Y S I S O F H O M O G E N A T E S F R O M
D I S C O R D A N T C A S E S
Nylon PVDF membranes prepared from protein gels
were probed for the presence of CK19 marker
(Table 4; Figure 2): 24 of the 81 discordant cases
(29.6%) were macrometastasis cases, and 57 of 81
were micrometastasis cases (70.4%). Homogenates
were available for 66 of 81 (81%) cases that were
discordant in the study group. Of the 66 informative
cases, 22 were macrometastasis cases, and 44 were
micrometastasis cases.
Histology-negative Metasin-positive cases (false-positive
cases
Protein lysates were available for 38 of 49 cases: 17
were macrometastasis cases, and 21 were
micrometastasis cases. Cytokeratin-related bands were
seen in 13 of the 17 macrometastasis cases and in
10 of the 21 micrometastasis cases. No cytokeratin-
related bands were seen in the remainder of the cases
(Table 4; Figure 2).
Pooled breast cancer
n = 1836 cases
Metasin & 3 level
histopathology
Concordant cases
Histology
& metasin
positive
n = 356
(19.4%)
Histology
& metasin
negative
n = 1372
(74.7%)
False +ve
Metasin
positive &
histology
negative
n = 49
(2.6%)
False –ve
Metasin
negative &
histology
positive
n = 32
(1.7%)
Discordant cases Assay fails
n = 1728 (94.6%) n = 81 (4.4%) n = 27 (1.5%)
Figure 1. Summary of clinical outcomes for pooled dataset of ana-
lytical validation cases and clinical validation cases undergoing
analysis with Metasin (n = 1836).
Table 2. Comparison of tumour volumes in concordant positive cases between histology and Metasin (n = 356)
Histology
Total, no. (%)Macrometastases, no. (%) Micrometastases, no. (%)
Metasin Macrometastases 277 (77.9) 28 (7.8) 305 (85.7)
Micrometastases 12 (3.4) 39 (10.9) 51 (14.3)
Total 289 (81.2) 67 (18.8) 356 (100)
Table 3. Marker distribution in macrometastasis and
micrometastasis cases; the table summarizes all of the
Metasin-positive cases (inclusive of Metasin-positive histol-
ogy-negative discordant cases) deemed to be macrometas-
tases and micrometastases, and the associated marker
distribution
Marker Macrometastases Micrometastases Total (%)
CK19 and
MGB
210 14 224 (55.3)
CK19 102 49 151 (37.3)
MGB 11 19 30 (7.4)
Total 323 82 405 (100)
CK19, cytokerain 19; MGB, mammaglobin.
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Histology-positive Metasin-negative cases (false-negative
cases)
Protein lysates were available for 28 of 32 cases: five
were macrometastasis cases, and 23 were
micrometastasis cases. Cytokeratin-related bands were
seen in four of five macrometastasis cases, and in
nine of 23 micrometastasis cases. No cytokeratin-
related bands were seen in the remainder of the cases
(Table 4; Figure 2).
A S S A Y F A I L U R E S : A N A L Y T I C A L A N D V A L I D A T I O N
G R O U P
Twenty-seven cases were deemed to be inconclusive
(27/1836, 1.5%), of which 20 were Metasin assay
failures. Seventeen of the 20 cases (0.9%) reported as
assay failures from the archived samples were mainly
attributable to the internal reference gene PBGD not
reaching the set Cq value, implying insufficient or
degraded RNA in the material submitted for molecu-
lar analysis. Of the remainder, many of these assay
failures were seen when insufficient tissue was pro-
vided or when fat was not adequately trimmed from
material submitted for molecular analysis. Histologi-
cal review of sections from selected assay failure
nodes showed that >50% of the node was replaced by
fat, in addition to <50 mg of nodal material being
submitted. The remaining three cases in the ‘invalid’
group were reported as positive on histological analy-
sis of parallel sections (two macrometastasis cases;
one micrometastasis case), suggesting possible tissue
selection bias. Seven other cases did not yield suffi-
cient tissue for histology. Two of these cases were
Metasin-positive (one micrometastasis case; one
macrometastasis case), and five were Metasin-nega-
tive. As these cases were not corroborated by histol-
ogy, these cases were excluded from the main study
group, and included in the invalid group.
Discussion
This validation study of >1800 SNLs assessed with
Metasin with parallel histology shows that the assay
is fit for purpose, with an overall discordance rate of
4.4%. This compares favourably with the discordance
rates published for Genesearch, an assay that is com-
parable to Metasin, with discordance rates of 9.2%
and 7.7%.20–22 Our data show that Metasin is at
least comparable to conventional histology, the cur-
rent gold standard. The molecular approach provides
a significant major advantage of speed over conven-
tional histology, enabling its use in the intraoperative
setting.21–24
Table 4. Discordance analysis by protein gel electrophoresis (see Figure 2); the table summarizes all of the Metasin and his-
tology discordant cases and outcome of the western blots of lymph node homogenates after protein gel electrophoresis and
probing for cytokeratin (CK19) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Outcomes are tissue allocation
bias (TAB), absence of CK19 protein or that Metasin did not detect CK19 & MGB RNA in the assay.
‘False positive’ (histology-negative/Metasin-
positive) ‘False negative’ (histology-positive/Metasin-negative)
Total no. 49 32
Homogenates for western
blots, no. (%)
38 (58) 28 (42)
Macrometastases Micrometastases Macrometastases Micrometastases
No. of cases (% of 66) 17 (26) 21 (32) 5 (8) 23 (35)
Outcome of western blots
for CK19
Positive Negative Positive Negative Positive Negative Positive Negative
No of cases (% of 66) 13 (20) 4 (6) 10 (15) 11 (17) 4 (6) 1 (2) 9 (14) 14 (21)
Positive clearances/total
clearances
0/9 3/4 6/7 0/3 0/4 0 1/4 1/6
TAB No CK19
protein
TAB No CK19
protein
Assay missed
diagnosis
TAB Assay missed
diagnosis
TAB
TAB, tissue allocation bias.
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Overall, Metasin has a sensitivity of 92% and a
specificity of 97%, with an NPV of 98% and a PPV of
88%. These figures compare favourably with those
for the cases examined with Genesearch in this study
(retrospective samples) and in published data.20–22
This contrasts with established methods used in the
intraoperative setting: FS and DAB cytology.6–9 A
meta-analysis of the published literature has indicated
that FS analysis8 has a sensitivity of 76% and that
imprint cytology6 has a sensitivity of 62%, with
marked divergence in the range of sensitivities and
specificities reported. A report on intraoperative FSs
examined by step sectioning and rapid immunostain-
ing of sections at 50 lm has demonstrated an NPV
value of 94%.11 However, implementation of this
approach is impractical in the UK district general hos-
pital diagnostic setting.
Currently, FS and DABc are alternative approaches
to Metasin. Although they are cheaper than Meta-
sin,18,19,33 both have significantly lower sensitivity
rates than the molecular approach. Unlike Metasin,
which is entirely carried out by trained BMSs, these
two methods are dependent on the availability of
trained histopathologists to read and report the slides
(s). In some NHS Trusts, surgical theatres are located
at sites remote from the laboratory, with no immedi-
ate access to consultant pathologists. In the UK, the
reluctance to embrace intraoperative testing has
been largely related to the cost of implementation of
the assays, capital costs, and the cost per test33 of
commercially available assays. In addition, there has
been a tendency for pathologists to adopt a very
conservative stance, and to be reluctant to embrace
this alternative approach. However, the driving force
for embracing this approach rests with the cost to
the NHS of the second operations19 (£5500) and
patient choice, which is largely ignored by
histopathologists.
49 false +ve cases
38 false +ve
homogenates
Ck19 NO Ck19
bands present bands
n = 23 (35%)
Macros
Tissue allocation bias
34.8%
Tissue allocation bias
22.7%
False positive
22.7%
False negative
19.6%
n = 13
micros
n = 10
Macros
n = 4
micros
n = 11
Macros
n = 4
micros
n = 9
Macros
n = 1
micros
n = 14
n = 15 (23%)
Ck19 NO Ck19
bands present bands
n = 13 n = 15
28 false –ve
homogenates
Discordant cases
n = 81 (4.4%)Metasin positive &
histology negative
32 false –ve cases
Metasin negative &
histology positive
Figure 2. Discordance analysis by protein gel electrophoresis (see Table 4).
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In implementing Metasin, we have elected to submit
parallel sections for histology. Discordance between
histology and molecular analysis is inevitable. Here,
we have investigated our discordant cases by detailed
western blot analysis, and have demonstrated that
>50% of these discordant cases can be ascribed to tis-
sue allocation bias. Twenty-three per cent of the dis-
cordant group classified as false-positive cases
(histology-negative; Metasin-positive) did not show
CK19 bands on western blot analysis (four
macrometastasis cases; 11 micrometastasis cases).
These 15 cases were subjected to axillary clearance. In
three of four patients from this group with
macrometastases, the axillary clearance specimens
showed positive nodes, implying that the ‘Metasin-
positive’ call was correct, and that the failure to detect
the metastasis by histology was probably attributable
to tissue allocation bias. The failure to detect cytoker-
atin bands in this material is not surprising, because
some of these protein lysates were nearly 6 years old.
This probably accounts for absence of cytokeratin
bands on western blotting in these samples.
The false-negative group (20% of the discordant
group) implies that, despite using two predictive
markers, we are missing a small number of CK19/
MGB-negative cases. Fortunately, these were detected
by parallel histology. Recent refinements to the assay
with Conformite Europeenne (CE) marked Metasin
reagents and refinements of polymerase chain reac-
tion conditions have resulted in the ability to detect
nearly half of these false-negative cases.
In establishing Metasin, we have mirrored the
Genesearch strategy by using more than one epithe-
lial marker, and we acknowledge that, even with the
use of two markers, there is a likelihood of missing
cases positive for tumour. We and others have real-
ized the shortcomings of using a single marker such
as CK19, as is used in some commercial assay
(s).24,34–39 It is therefore significant that a number of
cases (7.4%, 30 of 405 Metasin-positive cases) were
CK19-negative but MGB-positive. Had we used CK19
only, like the other commercial assay that is avail-
able,23 and subjected the whole node to the
assay,23,36 we are likely to have failed to detect these
30 cases positive only for MGB and the false-negative
cases by Metasin or by histology.
Here, we have shown that Metasin is accurately
able to detect micrometastasis and macrometastasis
in nearly 89% of cases. Discordances between Meta-
sin and histology are inevitable if the strategy of
using alternate sections for molecular and histological
examination is implemented. The 11% discordance is
a drawback, and should be recognized as a disadvan-
tage of adopting the approach of examining parallel
sections by conventional histology. Improvements in
axillary sonography have increased the rate of preop-
erative detection of metastatic disease in the axilla,
and have hence reduced the numbers of positive
intraoperative SLN cases.14–16 The numbers in the
discordant group (owing to small tumours) ascribed
to tissue allocation bias and assay misses are likely to
continue. This is despite the overall reduction in posi-
tive axillas undergoing SLN sampling regardless of
the improvements in axillary sonography.14–16
Assay failures are inevitable, and are no different
from the indecision of pathologists examining FSs
who inform the surgeon to await paraffin sections.
Overall assay failures were of the order of 1.5% (in-
clusive of analytical and prospective validation
groups), which is not surprising, as the archived
homogenates and RNA were 4–6 years old. RNA
degradation was evident in this historical group by
the failure of PBGD amplification, accounting for the
high failure rate in this ‘archival group’, contrasting
with 0.7% of assay failures in the prospective valida-
tion group. Very small lymph nodes (<50 mg) and
lymph nodes that are largely replaced by fat con-
tribute to assay failure, owing to insufficient amplifi-
cation of PBGD, similarly to what occurs with
Genesearch. For these reasons, we have assiduously
examined parallel sections of tissue for Metasin and
histology, and continue to advocate the use of paral-
lel sections for histopathological examination.
The rationale for intraoperative testing and axillary
clearance has been recently challenged by the find-
ings of the Z0011 study,40 advocating a conservative
approach to axillary clearance, favouring radiother-
apy and or systemic chemotherapy. Currently in the
UK, there are two schools of thought: some follow
the outcome of the Z0011 study40 with a conserva-
tive approach, and others do not, with some centres
adopting a more interventional stance, performing
axillary clearances for micrometastases. Prospective
studies are underway to evaluate the role of axillary
clearance in SLN-positive cases.
Conclusion
The treatment of patients with breast cancer is con-
tinually evolving. There has been a significant
change in breast cancer management worldwide,
with the emphasis drifting towards a less radical
approach to surgical treatment over the last 10–
15 years. However, current clinical practice still
requires the assessment of SLNs.41,42 The large data-
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set described in this article confirms the high sensitiv-
ity and specificity of Metasin, and a low level of dis-
cordance with histopathology. The ability to diagnose
metastatic disease with considerable sensitivity
enables the surgeon to consider axillary clearance as
a one-step procedure. These advantages, together
with patient choice and NHS savings, make a com-
pelling argument for the adoption of this approach.
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